Navigation Links
Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
Date:11/27/2007

ROCKVILLE, Md., Nov. 27 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia. Acceptance of the NDA confirms that the application is sufficiently complete for FDA review.

About Schizophrenia

Schizophrenia is a chronic, severe and disabling brain disorder that affects approximately one percent of Americans. Patients suffering from schizophrenia exhibit a range of symptoms, which include positive symptoms such as hallucinations, delusions, negative symptoms such as emotional withdrawal and cognitive symptoms associated with significant impairment in social and occupational functioning.

Unmet Needs in Schizophrenia

Although there are many drugs approved to treat schizophrenia, including the commonly prescribed "atypical antipsychotics," a high degree of dissatisfaction remains among physicians and patients. The recent CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) study, conducted by the National Institute of Mental Health (NIMH) and reported in The New England Journal of Medicine, evaluated several antipsychotic medications and revealed that 74% of patients taking antipsychotics discontinued treatment within 18 months, primarily because of insufficient efficacy and tolerability issues.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company with a focus on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product ca
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets ... Type of Material, by Technology, by Application & by Region- ... offering. The demand for membranes is estimated ... the market to $29.31 billion Membrane technology was ... such as water filtration and kidney dialysis. In modern times, ...
(Date:8/19/2014)... , Aug. 19, 2014 Avizia, Inc., ... that it has closed an equity financing round led ... Middleland Capital. The new funding will be used to ... this financing round, Avizia welcomes Edward Kennedy , ... of directors. He joins Leonard Kurtzman , CFO ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Global Membranes (MF, RO, UF, Gas Separation, Dialysis, NF) Market - Forecasts to 2019 2Avizia Closes Funding Round 2Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
... Inhibitex, Inc. (Nasdaq: INHX ) today announced that ... its common stock, at a purchase price of $4.10 per ... proceeds to Inhibitex from the sale of the shares, after ... to be approximately $44 million.  Inhibitex has granted the underwriters ...
... April 7, 2011 Vystar® Corporation ... Rubber Latex (NRL), a patented, all-natural raw latex ... non-rubbers found in natural rubber latex, has appointed ... (Logo: http://photos.prnewswire.com/prnh/20100203/CL48049LOGO) Ms. Kearney is ...
Cached Medicine Technology:Inhibitex Prices $47 Million Public Offering 2Inhibitex Prices $47 Million Public Offering 3Vystar® Corporation Appoints Joanne Kearney as Vice President of Marketing 2Vystar® Corporation Appoints Joanne Kearney as Vice President of Marketing 3
(Date:8/20/2014)... Mass., (PRWEB) August 20, 2014 ... new report, PHOTONIC SENSORS AND DETECTORS: TECHNOLOGIES ... and detectors market is expected to grow to ... annual growth rate (CAGR) of 15.9%. Increasing ... region. , With a rapidly expanding range of ...
(Date:8/20/2014)... The Institute for Integrative Nutrition ... to announce its new partnership with California ... university offering graduate programs featuring flexible learning. Graduates ... now eligible to receive six graduate credits towards ... , “I’m so thrilled to announce this new ...
(Date:8/20/2014)... One Call Alert expands its line of personal emergency response ... device that connects customers to the help they need with ... 365 days a year. , ResCube can go anywhere—whether inside ... the T-Mobile nationwide network like a cell phone, so it ... with the other One Call Alert systems, ResCube wearers create ...
(Date:8/20/2014)... 19, 2014 (HealthDay News) -- Taking the ... of dying from heart-related causes, a new study suggests. ... year, the findings require urgent confirmation, said the Danish ... actual risk is small and that guidelines for the ... more information is available. One heart expert wasn,t ...
(Date:8/20/2014)... Plymouth University to be an official charity partner. Brain ... awareness of, and funding for, scientific research into brain ... A range of events and activities organised by the ... of staff and students, as well as other University ... The involvement of the wider community across the South ...
Breaking Medicine News(10 mins):Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Antibiotic Might Raise Heart Risks for Some 2Health News:Plymouth University chooses Brain Tumour Research as official charity 2
... Tenn., Dec. 16 Healthcare Management Systems,Inc.(R) (HMS) announced ... supply a full system of integrated clinical and financial ... their new, integrated HMS,system reinforces their commitment to providing ... Kimball Health Services has some healthcare ...
... reports that at its Annual General Meeting held today, shareholders overwhelmingly approved all of ... , , All seven Board members were re-elected ... , , , Donald H. Segal ... Officer, Kenneth A. Cawkell Director and Corporate ...
... this season of giving and sharing, St.,David,s Community Health ... million in grants to area nonprofit organizations that provide,access ... "Especially this year, we are ... for Central Texans," said Earl Maxwell, CEO of St. ...
... the largest privately held spinal implant manufacturer in the ... as Chief Financial Officer. Ms. DiCicco brings extensive experience ... manufacturer to the executive team at Globus. For the ... Nash Corporation (Nasdaq: KNSY ), a leading ...
... Inc.,(NYSE: STI ) announced today a ... take control of their healthcare costs. The,SunTrust Health ... a healthcare payment card, integrated account,management, online healthcare ... trusted custodial partner. , ...
... 2009 issue, The Journal of Nuclear Medicine SNM,s ... "This change to the publication allows the generous ... and organization of research reports," said Heinrich R. Schelbert, ... Nuclear Medicine . "Most important and critical, it strengthens ...
Cached Medicine News:Health News:Kimball Health Services Selects HMS to Provide Information Technology Infrastructure 2Health News:Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update 2Health News:Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update 3Health News:Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update 4Health News:Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update 5Health News:$5.15 Million Provided to Support Local Health Care Needs 2Health News:$5.15 Million Provided to Support Local Health Care Needs 3Health News:$5.15 Million Provided to Support Local Health Care Needs 4Health News:Globus Medical Strengthens Executive Team with Appointment of CFO 2Health News:SunTrust Introduces Health Savings Accounts for Employers Seeking to Take Control of Healthcare Costs 2Health News:SunTrust Introduces Health Savings Accounts for Employers Seeking to Take Control of Healthcare Costs 3Health News:Journal of Nuclear Medicine premiers new, full-color design 2
... design and reduced dimensions provide ... control of IOL while grasping ... the optic. Curved shafts with ... curved. Smooth, flat, cross action ...
... implanting the haptic loop beneath the ... bag without wrist twisting. Angled 45 ... placed in the same vertical plane ... action handle with dull finish. Most ...
Smooth colibri tip used to grasp and subsequently retract the capsule during nucleus delivery. Serrated handle with polished finish....
Two rows of teeth on jaws provide a firm purchase on the nucleus fragment for removal. Flat handle with dull finish....
Medicine Products: